💨 Abstract
India's Sun Pharmaceutical Industries is acquiring U.S.-based Checkpoint Therapeutics, an immunotherapy and targeted oncology company, in a deal worth up to $355 million. The acquisition aims to strengthen Sun Pharma's presence in the oncology sector.
Courtesy: theprint.in
Summarized by Einstein Beta 🤖
Suggested
This Bengaluru startup's leading India's nuclear fusion research—to light up a billion homes
‘Vague, confusing, and did nothing to improve my work’: how AI can undermine peer review
Russian forces advance further in Kursk, pro-Russian war bloggers say
Stocks slip, yen gains on Trump trade war, China deflationary woes
Rohit pleased with how his team handled speculations
Ruckus in Odisha assembly, House adjourned till 12.09 pm
6 labourers killed, 11 injured as truck overturns in Maharashtra
Lok Sabha adjourned for 30 minutes due to protests by DMK members over remarks by Pradhan
CPI(M) leader Padmakumar expresses dissent over state committee exclusion
US condemns attacks on Syrian minorities as coastal violence escalates
Powered by MessengerX.io